Luseogliflozin 5mg
Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM).
| Trivial name | Luseogliflozin 5mg |
| Catalog Number | A13476-5 |
| Alternative Name(s) | D-Glucitol, 1,5-dideoxy-1,5-epithio-1-C-(5-((4-ethoxyphenyl)methyl)-2-methoxy-4-methylphenyl)-, (1S)- |
| Molecular Formula | C23H30O6S |
| CAS# | 898537-18-3 |
| SMILES | CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C |
| Size | 5mg |
| Supplier Page | http://www.adooq.com/luseogliflozin.html |